natgillin/translations-raw huggingface dataset:
modulating the signal frame by an Orthogonal Frequency Division Multiplexing, OFDM, method; and transmitting the modulated signal frame, wherein a transmission delivery system descriptor including the identifier of the PLP, the identifier of the transmission system, and an active OFDM symbol duration field in a TS loop of the NIT maps transport streams to PLPs in data slices of the transmission systems. 
modulaciju okvira signala pomoću ortogonalne modulacijske tehnike u frekvencijskoj domeni (OFDM); i odašiljanje moduliranog okvira signala, gdje deskriptor C2 dostavnog sustava, uključujući identifikator PLP-a i identifikator C2 sustava u TS petlji NIT mapa, prenosi tokove do PLP-ova u podatkovnim komadima C2 sustava.
It is further disclosed that the light stream may be rinsed with a rinse solution stream comprising water while draining the dirty stream from the light stream. 
Proces iz bilo kojeg od patentnih zahtjeva 1 do 6, gdje je lagani tok ispran mlazom otopine za ispiranje koja sadrži vodu uz dreniranje nečistog toka iz laganog toka.
extract of Hippophae rhamnoides enriched with derivatives of ellagic acid; lipophilic extract of Echinacea angustifolia. Compositions as claimed in claims 1 and 2, wherein the various components are present in the following intervals (by weight per unit dose): 
Pripravci kako su navedeni u patentnim zahtjevima 1 i 2, naznačeni time da su razne komponente prisutne u sljedećim rasponima (masa po jedinici doze): a) benzofenantridinski alkoloidi: od 1 do 5; b) ekstrakt Hippophae rhamnoides: od 10 do 100; c) lipofilni ekstrakt Echinacea angustifolia: od 0.2 do 2.
The mixture is kept under stirring for 6 hours, the solvent is evaporated off and the residue is freeze-dried, thereby obtaining the final compound as a white solid. 
Smjesa je miješana 6 sati, otapalo je upareno a ostatak je liofiliziran i time je dobiven konačni spoj kao bijela krutina.
The pharmaceutical composition of claim 15, wherein the montelukast sodium is present in an amount of about 5% by weight, the lactose monohydrate is present in an amount of about 62% by weight, the hydroxypropylcellulose is present in an amount of about 2% by weight, the starch is present in an amount of about 18% by weight, the sodium starch glycolate is present in an amount of about 9% by weight, the magnesium stearate is present in an amount of about 1% by weight, and the coating agent is present in an amount of about 3% by weight. 
Farmaceutska kompozicija prema patentnom zahtjevu 13, naznačena time što je montelukast natrij prisutan u količini od oko 5 težinskih %, laktoza monohidrat je prisutna u količini od oko 62 težinska %, hidroksipropilceluloza je prisutna u količini od oko 2 težinska %, škrob je prisutan u količini od oko 18 težinskih %, natrijev škrob glikolat je prisutan u količini od oko 9 težinskih %, magnezijev stearat je prisutan u količini od oko 1 težinski % i sredstvo za oblaganje je prisutno u količini od oko 3 težinska %.
Results showed a Candida superinfection in 14 patients (15%) of placebo group and respectively in 9 patients (9%) of active group. 
Rezultati su pokazali superinfekciju Candidom u 14 pacijentica (15 %) placebo skupine odnosno u 9 pacijentica (9 %) aktivne skupine.
The polymeric composition according to claim 1, wherein the polyolefin is present in an amount ranging from 10% to 30% by weight. 
Polimerni sastav prema bilo kojem od zahtjeva od 1 do 4, naznačen time što je poliolefin prisutan u količini u rasponu od 10 % do 30 % po masi.
towards the said horizontal arm 121, and on the back side, and is further provided with a lower appendix 112 A projecting downwards. 
prema navedenom horizontalnom kraku 121,1 straga, te također sadrži donji izdanak 112A, koji se pruža prema dolje.
providing mammalian cells, wherein the cells comprise a first expression vector and a second expression vector; and inducing expression of the FSH mutant, 
(a) pružanje stanica sisavca, pri čemu stanice sadrže prvi ekspresijski vektor i drugi ekspresijski vektor; i
The alumina was washed with DCM then EtOAc and the fractions evaporated to dryness. 
Aluminij je bio ispran s DCM i tada s EtOAc, a frakcije su bile uparene do suhoće.
Apparatus according to claim 28, characterized in that said detecting means (300, 3001) for currents in al least a conductor connected to the load (16) comprise a current transformer. 
Uređaj u skladu sa zahtjevom 29, naznačen time da spomenuto sredstvo za otkrivanje struja (300, 3001) barem u vodiču koji je spojen na trošilo (16) sadrži strujni transformator.
The process of claim 29, wherein at least a portion of the substantially inert gas is heated and then introduced to the pyrolysis zone. The process of claim 1 or 4, the process further comprising combining at least a portion of the condensable vapors, in at least partially condensed form, with the cooled pyrolyzed solids, to increase the carbon content of the high-carbon biogenic reagent. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time što navedeni postupak nadalje uključuje kombiniranje najmanje dijela navedenih kondenziranih para, u najmanje djelomično kondenziranom obliku, s navedenim ohlađenim piroliziranim krutim tvarima i/ili s navedenim toplim piroliziranim krutim tvarima, kako bi se povećao sadržaj ugljika u navedenom biogenom reagensu bogatom ugljikom.
In further embodiments, compounds of the invention are agonists of the RUP25 receptor. 
U daljnjim oblicima, spojevi izuma su agonisti RUP25 receptora.
Pearlitic rail according to any one of the preceding claims consisting of 0.90 % to 0.95 % carbon, 0.82 % to 0.92 % silicon, 0.80 % to 0.95 % manganese, 0.08 % to 0.12 % vanadium, 0.003 to 0.007 % nitrogen, at most 0.015 % phosphorus, 0.008 to 0.030 % sulphur, at most 2 ppm hydrogen, at most 0.10 % chromium, at most 0.004 % aluminium, at most 20 ppm oxygen, the remainder consisting of iron and unavoidable impurities 
Perlitna tračnica prema bilo kojem prethodno navedenom patentnom zahtjevu, naznačena time da se sastoji od 0.90 do 0,95% ugljika, od 0.82 do 0.92% silicija, od 0.80 do 0.95% magnezija, od 0.08 do 0,12% vanadija, od 0,003 do 0.007% dušika, najviše 0.015% fosfora, od 0.008 do 0.030 sumpora, najviše 2 ppm vodika, najviše 0.10% kroma. najviše 0.004% aluminija, najviše 10 ppm kisika i ostatka koji čine željezo i neizbježna onečišćenja.
Thus, the present invention relates to compounds of the formula (I) oligosaccharide-spacer-A (I), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa activity per se; the spacer is an essentially pharmacologically inactive flexible linking residue having a chain length of 10 to 70 atoms; 
(ID, gdje R? je OSO; ili (1-8C)alkoksi, gdje naboj kompenziraju pozitivno nabijeni protuioni, te gdje se pentasaharidni ostatak dobiva iz pentasaharida koji ima (uz posredstvo AT-III) anti-Xa aktivnost kao takav; razmaknica je uglavnom farmakološki inaktivni fleksibilni vežući ostatak, s lancem dugim 10 do 70 atoma;
A combination according to claim 1 wherein the anti-alpha-4 integrin antibody is an antibody Fab fragment. 
Kombinacija u skladu sa zahtjevom 1, naznačena time, da anti-alfa-4 integrin antitijelo je Fab fragment antitijela.
The product was filtered and dried in vacuum (30-50 mbar) at a temperature of 30-35°C. The drying was controlled by measuring the water content as described in Example 8 and the loss on drying to get 0.98 g donepezil hydrochloride of form IV. 
Dobiveni produkt je bio filtriran 1 osušen u vakuumu (30-50 mbara) na temperaturi od 30-35 *C. Sušenje je bilo kontrolirano mjerenjem količine vode kako je opisano u Primjeru 8 i gubitka tijekom sušenja čime je dobiveno 0,98 g donepezil hidroklorida oblika IV.
identifying fluctuations in said image data during said step (b) indicative of actual rotation of the container. 
(c) identificiranju fluktuacija u navedenim slikovnim podacima iz koraka (b), indikativnim za stvarno zakretanje spremnika.
A membrane module that is immersed in a liquid to be treated and performs filtration, comprising: 
Membranski modul (34) koji se može uranjati u tekućinu koja se treba obraditi radi provođenja filtriranja, koji sadrži:
The process according to item 1, wherein step (b) is performed by reacting B with methanesulfonyl chloride, in presence of triethylamine as base, in a mixture of MTBE and toluene in 3:2 volume ratio, at a temperature from about 5°C to about 10°C. 6. 
Postupak prema zahtjevu 1, gdje se korak (b) provodi reagiranjem B s metansulfonil kloridom, u prisutnosti trietilamina kao baze, u smjesi MTBE i toluena u omjeru 3:2, pri temperaturi 5*C€ do 10*C.
A production method for an industrial convenience ready-to-eat food product, having a minimum water activity of 0,80 and comprising a filler, free of preservative and emulsifier, characterized in comprising the process steps of; 
< Postupak proizvodnje industrijski prehrambenog proizvoda gotovog za jelo, naznačen time da ima minimalnom aktivnosti vode od 0,80 i sadrži punilo, bez konzervanasa i emulgator, karakteriziranu koracima postupka; a) - priprema i kuhanja pekarskog proizvoda (1), b) dase dobije punilo (2), 1)
In the case of copolymer-1 the most characteristic side effects, again are the skin reactions and local pain - as consequences of the subcutaneous administration, further, - redness of face, pressure in the thorax, palpitation and laboured respiration may occur (Johnson et al., Neurology 45, 1268-1276, (1995); Bornstein et al., N. Engl. 
U slučaju kopolimer-1 najkarakterističnija nuspojava ponovno je reakcija kože i lokalna bol-kao posljedica subkutane administracije, nadalje, crvenilo lica, pritisak u prsima, palpatacija i otežano disanjese može pojaviti (Johnson et al., Neurology 45, 1268-1276, (1995); Bornstein et al., N. Engl.
Preferred compounds are substituted 2-thioxo-imidazolidine-4-ones, or their spiro analogues, expressed by the general formula 1.1 and 1.2, 
Spojevi iz patentnog zahtjeva 1 koja su (R)-stereoizomeri supstituiranih 2-tiokso-imidazolidin-4-ona opće formule 1.1 ili 1.2,
the adjuster includes an adjuster mandrel that is rotatable relative to the hollow housing and has an external portion that is engageable from outside the hollow housing via a side thereof, and an adjuster portion that is threadedly connected to the jar mandrel such that rotation of the adjuster mandrel relative to the jar mandrel alters the length of the chamber and hence the degree of compression of the compression spring. 
- = podešivač sadrži vreteno podešivača, koji se može okretati u odnosu na šuplje kućište i ima vanjski dio koji je zahvaćen izvan šupljeg kućišta preko boka kućišta, i dio podošivača, koji je navojem povezan za vreteno udaraca, tako da okretanje vretena podešivača u odnosu na vreteno udaraca mijenja dužinu komore i time stupanj sabijanja kompresijske opruge, i
The heterocyclic compound according to claim 1, which is selected from the group consisting of: 
Heterociklički spoj ili njegova sol prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
contacting off-gas from the pyrolysis and/or gasification steps with an oxidation catalyst to convert carbon monoxide and hydrocarbons in the off-gas into carbon dioxide and water; 
- < dovođenje plina oslobođenog tijekom faze pirolize i/ili uplinjavanja u kontakt s nekim oksidacijskim katalizatorom da bi se ugljični monoksid i hidrokarboni iz oslobođenog plina konvertirali u ugljični dioksid i vodu;
A process for making a sealed container according to any of claims 11 to 16, wherein the process comprises: 
Postupak za izradu posude prema bilo kojem od Zahtjeva 7 do 11, gdje postupak sadrži:
The xylitol is preferably incorporated into the sorbitol/xylitol mixture in non-crystallising form. 
Ksilitol je poželjno ugrađen u sorbitol/ksilitol smjesu u ne-kristalizirajućem obliku.
Use of an anti-alpha5beta1 antagonist antibody in the preparation of a medicament for treating a disease having excessive angiogenesis in a subject by administering an anti-VEGF antagonist antibody and an anti-alpha5beta1 antagonist antibody, wherein the anti-VEGF antagonist antibody and the anti-alpha5beta1 antagonist antibody are administered in concurrent treatment cycles. 
Uporaba protutijela antagonista anti-alfaSbetal, naznačena time, da je za proizvodnju lijeka za liječenje bolesti koja ima prekomjernu angiogenezu kod pojedinca, pomoću davanja protutijela antagonista anti-VEGEF i protutijela antagonista anti-alfaSbetal, pri čemu se protutijelo antagonista anti- VEGF i protutijelo antagonista anti-alfa5beta1 primjenjuju u sukladnim ciklusima liječenja.
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule or expression vector for the use according to claim 22, wherein the disease is B cell non-Hodgkin's lymphoma. 
Protutijelo, imunokonjugat, farmaceutski pripravak, bispecifična ili multispecifična molekula za uporabu u skladu s patentnim zahtjevom 17, naznačeno time da je bolest non-Hodgkinov limfom B stanica.
The pharmaceutical composition of claim 24, further comprising another anti-viral, antibacterial, anti-fungal or anti-cancer agent, or an immune modulator. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 24, naznačen time, da nadalje sadrži drugo protu- virusno, protu-bakterijsko, protu-gljivično sredstvo ili sredstvo protiv karcinoma ili imunomodulator.
An isolated antibody or a functional protein as claimed in claim 1 comprising a heavy chain variable region CDR1 amino acid sequence selected from the group consisting of SEQ ID NOs: 2-7; and 
(a) varijabilno područje jakog lanca CDRI aminokiselinske sekvence odabrane iz skupine koju čine od SEQ ID NO:2 do SEQ ID NO: 7; 1
admixing the mixture obtained in step (b) to obtain the liquid preparation in the form of an aqueous solution. 
miješanje dobivene smjese iz koraka b) za dobivanje tekućeg pripravka u obliku vodene otopine koja ima pH vrijednost od 5,5 do 8,5.
In particular, the atomiser 11 is formed as a portable inhaler and preferably operates without a propellant gas. 
Posebno, atomizer 11 je izrađen kao prenosivi inhalator i radi ponajprije bez potisnog plina.
According to another inventive aspect, said actuation element executes at least two successive displacements, in each case as a result of the application of a certain actuation force, in each case resulting in at least one previously defined flow passageway for the flow to entry in the capsule, and said, at least one, previously defined flow passage out of the capsule, respectively. 
Kapsula u skladu s patentnim zahtjevom 1, naznačena time, da element za pokretanje (5; 5e, 5s) može izvesti najmanje dva uzastopna pomaka, u svakom slučaju kao rezultat primjene određene aktivacijske sile (F1, F2), oslobađajući najmanje jedan protočni kanal (S1) za ulaz protoka unutar kapsule (1) i najmanje jedan protočni kanal
is an aryl group or a heteroaromatic group, which may have a substituent selected from a group consisting of a halogen atom, a cyano group, a nitro group, a carboxyl group, a group of -Q4-A4(R1g)R1h and a group of -Q5-Ara; 
je aril skupina ili heteroaromatska skupina, koje mogu imati supstituent odabran iz grupe koju čine halogen atom, cijano skupina, nitro skupina, karboksil skupina, skupina -Q4-A4(R1g)R1h i skupina -Q5-Ara; i sve ostale skupine su kako su definirane u zahtjevu 1;
a peptide consisting of the amino acid sequence of SEQ ID NO: 32 when presented on an MHC molecule. A pharmaceutical composition comprising a T-cell mixture according to claim 1, and a pharmaceutically-acceptable carrier, diluent and/or excipient. 
Farmaceutska kompozicija koja sadrži peptidnu smjesu iz bilo kojeg od patentnih zahtjeva 1-3, ili smjesu T stanica iz patentnog zahtjeva 4 1 farmaceutski prihvatljiv nosač, razblaživač i/ili ekscipijens.
The method of claim 26, wherein the neurological disorder is a storage disorder, chronic pain, epilepsy, multiple sclerosis, a proteinopathy, or a demyelinating disorder. A binding molecule comprising: 
Vezivna molekula namijenjena upotrebi u skladu s patentnim zahtjevom 20, naznačena time što neurološki poremećaj označava poremećaj pohrane, kroničnu bol, epilepsiju, multiplu sklerozu, proteinopatiju ili demijelinizirajući poremećaj.
Ulipristal or a metabolite thereof is useful for preventing or treating anemia in patients afflicted with uterine fibroids. 
Ulipristal acetat za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida.
Aryl is phenyl optionally substituted with a substituent selected from the group consisting of halo, C1-4alkyl, —O—C1-4alkyl and —SO2—C1-4alkyl; 
pri čemu Aril je fenil po izboru supstituiran sa supstituentom odabranim iz skupine koju čine halo, C1-4alkil, -O-C1-4alkil i -SO2-C1-4alkil;
The process according to claim 1, wherein a total amount of the calcium stearate introduced in step (a) and the mixture of stearic acid and palmitic acid introduced in step (b) is 3 to 4 mg of total calcium stearate and mixture of stearic acid and palmitic acid per m2 of mineral filler. 
Postupak prema bilo kojem od zahtjeva 1 do 19, naznačen time da je alifatska karboksilna kiselina koja se koristi u koraku (b) smjesa u omjeru 1:1 stearinska kiselina: palmitinska kiselina, a sol(i) alifatske karboksilne kiseline koja se koristi u koraku (a) je magnezijev ili kalcijev stearat.
wherein the viscosity of the composition is below 1000 mPas at a shear rate of 100 1/s and at a temperature of 20°C, and wherein the hydrophobic colloidal silica and the active agent are dispersed in the oil. 
pri čemu je viskoznost pripravka ispod 1000 mPas pri brzini smicanja od 100 1/s i pri temperaturi od 20°C, i pri čemu su hidrofobna koloidna silika i aktivno sredstvo dispergirani u ulju.
characterised in that the first fibre layer (4.1, 4.1', 4.1", 4.2, 4.2', 4.2", 4.3", 4.4", 4.5", 4.6", 14, 16, 18) is at least partially interspersed with a filter material (6) for binding mineral oil substances in such a manner that the fibre product (2, 2.1, 2.2, 2.3) has a migration value of at least less than 0.6 mg/kg, 
Upotreba filtarskog materijala (6) u pakiranju živežnih namirnica, naznačena time što je u vlaknastom proizvodu (2, 2.1, 2.2, 2.3) razasut filtarski materijal (6) za vezanje tvari mineralnog ulja radi smanjivanja migriranja tvari mineralnog ulja iz vlaknastog proizvoda (2, 2.1, 2.2, 2.3) u drugi proizvod do vrijednosti migriranja od najmanje manje od 0,6 mg/kg, gdje je vlaknasti proizvod karton, ljepenka i/ili papir.
A door unit for a display cabinet, the door unit comprising: a frame holding at least two sliding doors such that the doors can be slid between open and closed positions and the doors close different openings in the frame, the doors being offset from one another in a direction perpendicular to the sliding direction of the doors; and linking means for selectively linking the two doors such that when a first one of the doors is opened the linking means engages with the second one of the doors to pull it open also and when the second one of the doors is opened the linking means disengages such that the first door remains closed, and wherein the said two sliding doors are respectively an upper and a lower door. 
HR P20141017 T1 PATENTNI ZAHTJEVI Komplet vrata za izložbeni ormar, pri čemu se komplet vrata sastoji od: okvira koji drži najmanje dvoja klizna vrata tako da se vrata mogu klizno pomicati od položaja otvoreno do položaja zatvoreno i da vrata zatvaraju različite otvore na okviru, pri čemu se vrata odmiču jedna od drugih u okomitom smjeru u odnosu na smjer kliznog kretanja vrata; i od spojnog mehanizma za selektivno spajanje dvaju vrata tako da kada su prva vrata otvorena, spojni mehanizam pokreće druga vrata da se i ona otvore, a kada su druga vrata otvorena spojni mehanizam se otpušta tako da prva vrata ostaju zatvorena, pri čemu navedena dvoja klizna vrata čine gornja i donja vrata.
The arrangement as claimed in claim 4 wherein the open passage comprises an annular open passage extending around the first opening. The arrangement as claimed in claim 2 wherein the open passage extends around an inner surface of the first opening. 
Sustav za sprječavanje izbacivanja plina iz prvog otvora spremnika prema bilo kojem od zahtjeva 3 ili 4, pri čemu se otvoreni prolaz proteže oko unutarnje površine prvog otvora.
When using a system for cell cultivation comprising an external column, the external column may be removed from the system after performing step (d). 
Kada se rabi sustav za uzgoj stanica koji obuhvaća vanjski kolonu, vanjska kolona se može odvojiti od sustava nakon provođenja koraka (d).
They are further suitable as analgesics for the treatment of pain associated with, e.g., angina, menstruation or cancer. 
Oni su, nadalje, prikladni kao analgetici za liječenje boli povezane npr. s anginom, menstruacijom ili rakom.
is a hydrogen atom, a methyl group, an ethyl group, a propyl group, or a butyl group. 
R* je atom vodika, metilna skupina, etilna skupina, propilna skupina, ili butilna skupina.
opening or holding open the switching element or and setting the changeover switch in the first position; 
u koraku a) prekidački element (11) je otvoren, a sklopka za prebacivanje (2) zauzima prvi položaj;
A process according to claim 1 wherein the reduction is carried out by reacting a compound of formula II with sodium borohydride in the presence of an alcoholic solvent optionally mixed with water. 
Postupak prema zahtjevu 1 gdje se redukcija provodi reakcijom spoja formule II sa natrijevim borohidridom u prisutnosti alkoholnog otapala koje se po izboru miješa s vodom.
a second chamber separated from the first chamber, the second chamber configured to hold a reconstituting solution for reconstituting the lyophilized pharmaceutical product in the first chamber; 
drugu komoru (120) odvojenu od prve komore (110), pri čemu je druga komora (120) konfigurirana da sadržava otopinu za rekonstituiranje, za rekonstituiranje liofiliziranog farmaceutskog proizvoda u prvoj komori (110);
a path of travel (20) for the plurality of vehicles (16); 
putanje (20) više vozila (16);
The known dispenser comprises a chill chamber in which a pack containing carbonated drink, such as beer, can be placed. 
Poznati djelitelj sadrži hladnu komoru u koju se može smjestiti pakiranje koje sadrži gazirano piće, kao što je pivo.
The compound or salt of claim 69 wherein said myeloproliferative disorder (MPD) is polycythemia vera (PV). 
Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj policitemija vera (PV).
A pharmaceutical dosage form containing a pharmacologically active agent according to general formula (I) wherein R is -H or -CH3, or a physiologically acceptable salt thereof, 
PATENTNI ZAHTJEVI Farmaceutski oblik doziranja koji sadržava farmakološki aktivno sredstvo prema općoj formuli (D pri čemu je R -H ili -CHo, ili njihova fiziološki prihvatljiva sol, -
Inlet air temperature 
Temperatura ulaznog zraka
More particularly, these compressible lamellas 4 are formed of non-woven synthetic fibres 10 which are joined together by means of a synthetic resin and thus have a three-dimensional open fibre structure. 
Još posebnije, ove lamele koje se mogu komprimirati 4 su načinjene od sintetskih vlakana 10 koja nisu tkana i koja se zajedno spajaju pomoću sintetske smole i na taj način imaju trodimenzionalnu otvorenu strukturu vlakana.
A co-suspension for use according to claim 21 wherein the disease or disorder is COPD. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 25, naznačen time što je bolest ili poremećaj COPD.